In accordance with the Rules and Procedures of the Council of Experts, the Biologics Monographs 3 - Complex Biologics & Vaccines Expert Committee has revised the Fondaparinux Sodium monograph. The purpose of this revision is to change USP Fondaparinux Sodium System Suitability Mixture A RS to USP Fondaparinux Sodium System Suitability Mixture A Solution RS due to the formulation change.

Additionally, minor editorial changes have been made to update the monograph to current USP style.

The Fondaparinux Sodium Revision Bulletin supersedes the currently official monograph and will become official on August 1, 2022. As outlined in USP General Notices 3.10. Applicability of Standards, users may use early adoption and begin using the USP Fondaparinux Sodium System Suitability Mixture A Solution RS when it is released by USP.

Should you have any questions, please contact Hangsik Moon, Senior Scientist II (301-816-8323 or hangsik.moon@usp.org).